Cure My Disease

Don't miss your cure!

 Log in / Sign up

Banking blood, skin and spinal fluid to decode Parkinson's

NCT ID NCT05266872

Knowledge-focused Sponsor: Luxembourg Institute of Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers at the Luxembourg Institute of Health run a long-term observational study that gathers clinical, genetic, and digital data plus biological samples from people with Parkinson's disease and healthy volunteers. Participants include adults with typical Parkinson's or atypical parkinsonism and age- and sex-matched controls. The study stores blood, urine, stool, saliva, hair, skin biopsy, and cerebrospinal fluid samples in a biobank to help scientists study how Parkinson's starts and progresses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the collection works as planned, researchers could gain a shared resource for finding early Parkinson's biomarkers and testing future treatments.
What could go wrong
This is an observational study, so it will not test a treatment or produce cures on its own. Results depend on long-term follow-up and sample quality, and any biomarker leads may take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2014

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects with a neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism) and gender- and age-matched healthy controls.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism) * Subjects of all genders with a full capacity of consent * Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement * Subjects of at least 18 years of age at the time of inclusion Exclusion Criteria: * Refusal to sign the informed consent * Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion * Active cancer * Pregnant women * Underage subjects of less than 18 years of age * Refusal to comply with mandatory sample collection * For invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier de Luxembourg (CHL), "Parkinson's Research Clinic"

    RECRUITING

    Luxembourg, 1210, Luxembourg

  • Clinical and Epidemiological Investigation Center (CIEC)

    RECRUITING

    Luxembourg, 1445, Luxembourg

More trials for these conditions

Other studies related to the condition(s) this trial covers.